Crossmark

Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study

Crossref DOI link: https://doi.org/10.1186/s12933-025-02846-x

Published Online: 2025-07-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hong, Sangmo

Han, Kyungdo

Kim, Kyung-Soo

Park, Cheol-Young
Funding

Funding for this research was provided by:

Chong Kun Dang Pharmaceutical Corporation
License Information

Text and Data Mining valid from 2025-07-14

Version of Record valid from 2025-07-14
More Information

Article History

Received: 9 April 2025

Accepted: 3 July 2025

First Online: 14 July 2025

Declarations

:

: The study protocol was approved by the Institutional Review Board of the Kangbuk Samsung Hospital (KBSMC 2022-04-016), which waived the requirement for informed consent due to the use of deidentified data.

: Not applicable.

: None.

Document is current

Any future updates will be listed below